Literature DB >> 3276569

Clinical, histological and immunological studies in 50 patients with bullous pemphigoid.

S M Hadi1, R S Barnetson, D J Gawkrodger, U Saxena, P Bird, T G Merrett.   

Abstract

Fifty patients with bullous pemphigoid were investigated over periods of up to 7 years. Sequential studies of circulating basement membrane zone (BMZ) antibody titres revealed two groups of patients: 44% had a high initial titre (greater than 1:160) and 56% had a low initial titre (less than 1:160). Subjects with titres greater than 1:160 continued to have high titres, whereas in those with lower titres the BMZ antibodies usually became undetectable after 4 months. The BMZ antibody titres were of no prognostic value. High titres remained high even in patients who were in remission and off treatment, and in these subjects, there was no evidence of a change in the IgG subclass. The initial BMZ IgG antibody titres showed a highly significant correlation with total serum IgE concentrations. A significant correlation also existed between total serum IgE and IgG4 concentrations, although not between the serum IgE and the peripheral blood eosinophil count. No anti-BMZ antibody of IgE class was found, nor specific IgE against inhalants and foods identified, and the significance of the high total serum IgE remains unexplained. The majority of those followed for more than 2 years were able to stop their steroid therapy without further blistering: this confirms that pemphigoid tends to be a self-limiting disease. Nine patients had a recent history of malignant disease, and this is no more than would be expected for this age group of patients: however, 3 patients presented with pemphigoid and figurate erythema and all died of neoplastic disease, suggesting that such patients should be investigated thoroughly for neoplasia.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3276569     DOI: 10.1159/000248663

Source DB:  PubMed          Journal:  Dermatologica        ISSN: 0011-9075


  6 in total

Review 1.  Interventions for bullous pemphigoid.

Authors:  Gudula Kirtschig; Philippa Middleton; Cathy Bennett; Dedee F Murrell; Fenella Wojnarowska; Nonhlanhla P Khumalo
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

Review 2.  Bullous pemphigoid: from bench to bedside.

Authors:  Scott R A Walsh; David Hogg; P Régine Mydlarski
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  The distribution of IgG subclass autoantibodies in bullous pemphigoid analysed by immunofluorescence and immunoblotting.

Authors:  H Soh; H Hosokawa; H Miyauchi; H Izumi; Y Asada
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

4.  Bullous pemphigoid in an elderly patient with myelodysplastic syndrome and refractory anemia coupled with excess of blast.

Authors:  Yin Yin Lee; Ping Chong Bee; Chew Kek Lee; Manimalar Naiker; Rokiah Ismail
Journal:  Ann Dermatol       Date:  2011-12-27       Impact factor: 1.444

5.  Treatment of subepidermal immunobullous diseases.

Authors:  Donna A Culton; Luis A Diaz
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

Review 6.  The Intersection of IgE Autoantibodies and Eosinophilia in the Pathogenesis of Bullous Pemphigoid.

Authors:  Kelly N Messingham; Tyler P Crowe; Janet A Fairley
Journal:  Front Immunol       Date:  2019-10-04       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.